Spectrum Pharmaceuticals (SPPI) 10-Q2009 Q1 Quarterly report

Filed: 15 May 09, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. freshman Avg

New words: abated, Allergen, allocated, amortization, amortize, amortized, APB, ASP, awaiting, bad, binding, category, cell, CMS, codevelopment, collateral, component, concentrated, concentration, concert, core, CTI, directly, discount, disposing, disputed, disruption, diversification, employee, escrow, escrowed, eventually, experienced, firm, follicular, front, fully, hope, independent, India, infrastructure, innovative, installment, intangible, Kumaria, lead, leucovorin, low, lymphoma, Medicaid, medical, Medicare, metastatic, methodology, Mumbai, NHL, obsolete, OncoRx, opportunity, originally, overhead, palliative, PDUFA, pension, perspective, pertaining, Pharma, pool, postretirement, prepaid, prepay, prepayment, prolong, Quebec, rapid, recruit, reflected, remove, Restated, return, RIT, sBLA, segment, shalll, shortage, shorter, Shyam, Similarly, sNDA, source, stage, support, survival, sustainable, tender, tendered, tiuxetan, turnover, unamortized, unanticipated, unexercised, unpaid, usage, User, venture, writing, zevalin

Removed: abbreviated, achieving, acid, advice, announced, benign, Biotech, BPH, carcinoma, comparability, consistently, controlling, counteract, deconsolidated, deconsolidation, deferral, diminish, distinguish, earn, economic, EMEA, equivalent, European, exit, face, February, folic, gain, GPC, health, hypertrophy, identified, impaired, improve, inadvertent, initially, initiated, labeled, laboratory, launch, legal, likelihood, measuring, methotrexate, mix, NDA, NeoJB, orderly, osteosarcoma, overdose, ozarelix, parent, performing, prepare, procedure, progressive, prostatic, protocol, randomized, range, recurrent, reduction, relevance, rescue, retained, Sagent, satraplatin, September, submitted, sufficiency, sumatriptan, tablet, tolerability, toxicity, transfer, transparency, varying, warrant

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

SPPI similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.1

Certification

Pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. § 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned officer of Spectrum Pharmaceuticals, Inc. (the “Company”) hereby certifies, to such officer’s knowledge, that:

(i) the accompanying Quarterly Report on Form 10-Q of the Company for the quarterly period ended March 31, 2009 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Dated: May 15, 2009	/s/ RAJESH C. SHROTRIYA
	Rajesh C. Shrotriya
	Chairman, Chief Executive Officer and President

This certification accompanies the Quarterly Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934.